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Obesity is associated with lower transplantation rate and higher mortality in pediatric end 
stage renal disease patients.  Glucose-based peritoneal dialysis is the preferred method of 
dialysis for these patients, a therapy that can cause systemic glucose absorption.  It is 
unknown whether this absorption leads to weight change in pediatric patients.  We 
propose to examine whether Peritoneal Dialysis is associated with weight change in 
pediatric End Stage Renal Disease patients.  We will prospectively observe a cohort of 
children aged 2-17 who are starting peritoneal dialysis.  We will measure weight change 
after one year of dialysis, and compare these measurements to historical control 
groups.  With this proposed study, we hope to gain insight into whether peritoneal 
dialysis contributes to obesity, leading to decreased eligibility for kidney transplantation. 
This knowledge will allow modification of renal replacement therapy and ultimately lead 
to improved outcomes in pediatric peritoneal dialysis patients. 
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Chapter 1- Introduction 
 
Background: Childhood Obesity 
 
 Childhood obesity is a growing problem faced by our nation that poses significant 
adverse health effects.  For children aged 2-19, overweight is defined as body mass index 
(BMI) greater than or equal to the 85th (but less than the 95th) percentile BMI matched for 
age and sex of the child.1 Childhood obesity is defined as BMI greater than or equal to 
that of the 95th percentile for age and sex.1 In the United States, 31% of children aged 2-
19 years old are overweight or obese.2 According to the Centers for Disease Control 
(CDC), the prevalence of both childhood and adolescent obesity has been on the rise over 
the past 30 years, in this time period rising from 7% to 18% in children aged 6-11 and 
rising from 5 to over 20% in adolescents aged 12-19.3 Childhood obesity can contribute 
to the development of metabolic syndrome, type II diabetes mellitus, hypertension, and 
other adverse future health outcomes if the child continues to be obese in adulthood.4 
Prospective investigation of pediatric patients has shown that 77% of overweight children 
remain obese in adulthood.5 
Obesity in Pediatric End Stage Renal Disease 
 
In addition to the general pediatric population, the prevalence of obesity is also 
rising in pediatric End Stage Renal Disease (ESRD) patients undergoing Renal 
Replacement Therapy (RRT).6 A 2015 study demonstrates that obesity is rising in 
prevalence in pediatric RRT patients, while the prevalence of children being underweight 
is decreasing.6 This study performed a retrospective analysis of children initiating RRT 
between the years of 1995 to 2011 in the United States, and found that the prevalence of 
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obesity in this population has risen from 14% to 18% over this time period.6 The 
researchers also found that the prevalence of being underweight in this population has 
decreased from 12% to 9% over the 16 years of data that were analyzed retrospectively.6  
A 2005 retrospective analysis by Hanevold et al. found an increase in obesity 
among pediatric ESRD patients.7 The researchers defined obesity as BMI above 95th 
percentile according to the child’s age and gender, and obtained their data from the North 
American Pediatric Renal Transplant Cooperative Study database.7 Specifically, before 
1995 the prevalence of obesity in pediatric ESRD patients was measured at 8%.7 After 
1995, the prevalence increased to 12.4%.7 This study suggests that in the pediatric ESRD 
population, obesity is increasing in prevalence.   
A 2013 descriptive study by Bonthuis et al. examined the prevalence of various 
BMI ranges in pediatric patients undergoing RRT in Europe.8 The researchers found that 
the prevalence of overweight in all pediatric RRT patients was 20.8%, and the prevalence 
of obesity was 12.5%.8 Of note, the prevalence of underweight pediatric RRT patients 
was found to be 3.5%.8 
Adverse Effects of Obesity in Pediatric ESRD Patients 
 
In addition to the risks associated with obesity, children with ESRD face 
additional risk of adverse health outcomes due to their renal disease.  Research has shown 
that pediatric ESRD patients have a 30 times higher mortality rate than children without 
ESRD.9 Risk factors for death include use of dialysis, which increases the risk of death to 
four times higher than the risk of death of those treated with renal transplantation.9 
 Obese and overweight children with ESRD face additional hardships to the direct 
physiological and medical consequences of their renal disease and obesity.  Many 
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transplant programs use specific BMI ranges as a criteria to be considered for transplant, 
meaning that in order to be listed for transplant, a patient’s BMI must fall within the 
range defined by the individual transplant program they are using.  If a patient’s BMI 
rises above the acceptable range, they will be temporarily withheld from consideration 
for a transplant until their BMI decreases to within the acceptable range.  Although the 
exact requirements differ by transplant program (and are often based on current literature 
regarding safety of transplant procedure at extremes of BMI), an example of a BMI 
cutoff is 35 kg/square meters.10   
Retrospective analysis in 2015 found that increased BMI/obesity in children with 
ESRD is associated with lower transplantation rate and higher risk of death.6 This study 
found that obese children on RRT have a 1.17 times higher risk of death than children 
with normal BMI.6 Obesity was also found to be a barrier to living donor transplant in 
children, demonstrated by a decreased odds ratio of living donor transplant in obese 
children compared with non-obese children.6 This finding is an example of how obesity 
can act as a barrier to improved outcome, as living donor transplant has been shown to 
precipitate better outcomes with greater transplant graft (the transplanted organ) survival 
and greater patient survival.10 A 2013 study found that higher BMI at the time of 
transplantation is associated with poorer outcomes compared lower BMI.10 This study 
found transplant recipient BMI greater than or equal to 30 associated with higher risk of 
delayed graft function.10 It was also found that recipient BMI greater than or equal to 35 
is associated with higher risk of biopsy-proven acute rejection (cellular rejection of the 
transplanted kidney), death-censored graft failure (failure of graft resulting in return to 
dialysis or pre-emptive transplant), and all-cause graft failure (failure of graft from death, 
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return to dialysis, or pre-emptive transplant) after renal transplantation.10 Additionally, a 
2002 study by Mitsnefes et al. found that pediatric ESRD patients who were obese before 
renal transplant were more likely to have a lower glomerular filtration rate (GFR), which 
is a measure of how quickly blood is filtered through the kidney and indicates how well 
the kidney is functioning, one year after transplant.11 It is clear that obesity is a barrier to 
optimal outcome in pediatric ESRD patients, especially considering the fact that the goal 
of most children with ESRD is renal transplantation.    
The aforementioned study by Hanevold et al. investigated transplant outcomes in 
obese versus nonobese children aged 2-17, and found that obese children aged 6-12 had a 
higher risk of death after transplant when compared to nonobese children aged 6-12.7 
Within the high risk (of mortality) group of children, death was more likely to be 
attributed to cardiopulmonary causes.7 Additionally, the study found that in the obese 
group of children, graft loss from thrombosis was higher (19%) than in the nonobese 
group (10%).7 These data indicates that the presence obesity in children at the time of 
kidney transplant poses significant risk. 
In addition to barriers faced at time of transplant and after transplant, the presence 
of obesity in pediatric ESRD patients confers risk and worse outcomes in other ways.  A 
2000 study by Wong et al. found a higher risk of death at the extremes of BMI (both low 
and high) in pediatric ESRD patients.12 These results indicate that in pediatric ESRD 
patients, being overweight or obese is related to worse outcome, including mortality.12 
A 2007 literature review found that in adults, increased BMI (in particular, 
increased fat mass) is associated with worse PD outcomes.13 Researchers found that 
increased inflammation, increased incidence of peritonitis (inflammation of a patient’s 
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peritoneal membrane that can have an infectious etiology), and faster decline in RRF may 
contribute to worse outcomes.13 
A 2012 study by Hoogeveen et al. compared the effect of obesity on mortality 
between dialysis patients over 65 years of age and dialysis patients under 65 years of 
age.14 They found that obesity was associated with a higher mortality rate in the younger 
cohort compared to the older cohort.14 Specifically in the younger cohort, age-
standardized mortality was found to be 1.7 times higher in obese patients than those with 
normal BMI.14 In the older aged cohort, there was a smaller difference in mortality 
between obese dialysis patients and those with a normal BMI.14 This study shows that 
obesity may pose additional risk to younger dialysis patients, therefore there is a need to 
investigate the relationship between PD and weight gain in the pediatric population.   
  A 2015 study that prospectively followed adult PD patients, assessing their BMI 
at baseline and at one year after the start of PD, showed that obesity is associated with 
higher cardiovascular mortality.15 Specifically, the researchers associated a unit of BMI 
elevation with a 9% higher risk of cardiovascular mortality.15 Retrospective analysis 
demonstrates obesity to be associated with lower GFR after renal transplantation in 
pediatric patients, compared with normal weight pediatric patients’ GFR after renal 
transplantation.11 In addition, multiple studies show that metabolic syndrome (a group of 
risk factors that increase a person’s risk for heart disease, diabetes, and stroke) leads to 
increased cardiovascular mortality after renal transplantation.16 The development of 
metabolic syndrome in post-transplant patients is contributed to by obesity, and it goes 
without saying that being obese at the time of transplantation is a risk factor for this 
complication.16 
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 Other research has shown obesity to be associated with worse PD outcomes. A 
2008 study found higher BMI to be associated with lower peritoneal urea Kt/v (which is a 
measure of dialysis adequacy) in PD patients.17 A 2003 study in Australia and New 
Zealand found obesity to be associated with death and technique failure in PD patients.18 
This study demonstrated that greatest survival in PD patients was associated with a BMI 
of 20 kg/m2.18 Above and below a BMI of 20kg/m2, survival rates declined.18 Research 
also shows that higher BMI in PD patients is associated with increased risk of peritonitis, 
with higher BMI patients having a shorter time to peritonitis and a higher occurrence of 
peritonitis compared controls.19 
 A 2015 study found that adult PD patients who gain weight while on PD had a 
faster residual renal function (RRF) decline.20 The body weight percent increase 
significantly correlated with an increased rate of RRF decline and an increased hs-CRP (a 
biomarker of systemic inflammation) level.20   
 Considering the above evidence, there are numerous studies to indicate that 
overweight/obesity in both pediatric and adult PD patients increases risk for adverse 
outcomes.  This said, adding to the body of knowledge pertaining to whether or not PD 
causes weight gain in pediatric patients is necessary and vital to improving patient 
outcomes in this population. 
Statement of Problem   
 
The preferred treatment of ESRD in pediatric patients is renal transplantation.  As 
renal transplant is not readily available to all patients at the time of RRT initiation, 
pediatric patients often spend time on dialysis therapy while awaiting transplant.  
Peritoneal dialysis is the preferred method of dialysis in pediatric patients due to its 
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quality of life implications, as PD can be done in the patient’s own home and promotes a 
more flexible lifestyle for the patient, versus hemodialysis (HD) which must be done 
several times per week at a dialysis center.21 However, it is clear that transplantation is 
superior to PD in treating pediatric ESRD.  Studies have shown a higher mortality rate in 
PD versus transplant.21 Data from Australia and New Zealand found a mortality rate of 
5.9 per 100 patient years in PD patients, and a mortality rate of 1.1 per 100 patient years 
in patients who had been treated with a transplant.9 
The preferred osmotic agent in PD therapy is glucose, and has been since the start 
of PD use to treat ESRD.22 Peritoneal dialysis solutions are available with dextrose (the 
D-isomer of glucose) concentrations of 1.5, 2.5 and 4.25%, with corresponding glucose 
content of 1360, 2250, and 3860 mg/dl.23 Systemic absorption of glucose across the 
peritoneal membrane is a known phenomenon that can result from using glucose-based 
PD solution.  Although absorption of glucose across the peritoneal membrane depends on 
various individual characteristics of the membrane, previous research shows that over a 
four hour PD dwell, approximately two-thirds of intra-peritoneal glucose is absorbed 
systemically.23 A 1996 study found large variability in number of calories absorbed 
across the peritoneal membrane, with an average of 5.89 calories/kg.24 This same study 
found that an average of 19% of total energy intake originated from the dialysate (the 
fluid used during dialysis to remove molecules from a patient’s blood) with absorption 
across the peritoneal membrane.24 Others estimate that daily systemic glucose absorption 
during PD ranges from 50-80%, which translates to 100 to 200g of carbohydrates or 320-
640 kCal.25 Although this phenomenon of systemic glucose absorption during peritoneal 
dialysis is variable, it is a phenomenon that has been shown to exist.  Previous research 
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shows that this absorption is associated with dyslipidemia (abnormally elevated serum 
cholesterol or other lipids) and increased visceral fat accumulation in patients.25   
What has been observed about the relationship of the absorption itself to actual 
weight gain and in turn, obesity, in the adult population has yielded contradictory results, 
which will be discussed in Chapter 2.  Whether or not the use of glucose based PD 
solutions leads to weight gain in the pediatric ESRD population has not been thoroughly 
studied.  A far greater number of studies have investigated this relationship in the adult 
population compared to the pediatric population.  This said, the relationship of glucose-
based dialysate to weight change is unknown in the pediatric population.  The adverse 
effects of obesity in pediatric ESRD patients, which have been described in this chapter, 
amplify the need to study the relationship of PD and weight change in the pediatric 
population.      
Goals and Objectives 
 
The goal of this study is to improve the knowledge base used to prescribe renal 
replacement therapy to pediatric ESRD patients by investigating the relationship between 
glucose-based Peritoneal Dialysis and weight change.  Renal transplantation is associated 
with greater quality of life and survival in children with ESRD, compared to other 
methods of RRT21, but can be affected by obesity.  The relationship between PD use in 
children and weight change needs to be investigated to improve outcomes in this 
population.  We will investigate whether PD therapy causes weight change that is in 
excess of that predicted by normal growth expectations, and with secondary analysis 
investigate various baseline variables and their relationships with possible weight change 
during PD therapy.  
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The objectives of this study are: 
1. Compare actual weight change during the first year of PD therapy to expected 
weight change using CDC growth charts in a cohort of pediatric patients on PD 
therapy.   
2. Compare actual weight change during the first year of PD therapy to historical 
values of weight change during the 12 months prior to starting PD therapy in a 
cohort of pediatric patients on PD therapy.   
3. Investigate how starting BMI, starting age, and dialysate glucose concentration 
affect weight change in pediatric patients undergoing PD therapy. 
Hypothesis 
 
We hypothesize that glucose-based peritoneal dialysis causes excess weight gain 
in pediatric ESRD patients during the first 12 months of PD therapy.   
Definitions 
 
End Stage Renal Disease (ESRD):  The last stage of chronic kidney disease, which often 
requires dialysis or transplant for patient survival. 
Hemodialysis (HD): Use of a synthetic, extracorporeal membrane to remove waste and 
excess fluid from a patient’s blood. 
Intra-peritoneal: Inside the peritoneal space. 
Peritoneal Dialysis (PD):  Administration of dialysate into a patient’s peritoneal space, 
and use of the patient’s peritoneal membrane to filter waste from their blood. 
Peritoneal Space:  A potential space between the parietal and visceral peritoneum, which 
are two membranes that surround a patient’s abdomen and pelvis. 
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Peritoneal Dialysis Dwell: The time, prescribed by the patient’s nephrologist, that the 
dialysate sits in a patient’s peritoneal space during peritoneal dialysis. 
Renal Replacement Therapy (RRT): Medical treatment of End Stage Renal Disease that 
replaces some functions of the kidney that are lost due to the severity of the disease 
includes dialysis and kidney transplantation. 
Residual Renal Function (RRF): A measure of the remaining ability of the kidney to filter 
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Chapter 2- Review of the Literature 
 
Introduction and Search Criteria 
 
We performed a systematic review of the literature using Ovid MedLine, Ovid 
Embase, and PubMed@Yale, as well as the bibliographies of reviewed articles.  We 
reviewed articles published from 1985 to present that were either published in English or 
translated into English.  The keywords used to search these databases are listed as 
follows: peritoneal dialysis, body fat, body weight, body composition, body mass index, 
change, end stage renal disease, children, and pediatric. 
PD Use and Weight Change in Adult Patients:  Part One 
 
 The relationship between glucose-based PD and weight change has been 
investigated in numerous studies in the adult population.  This section will provide a 
detailed literature review of past research that has investigated this relationship in the 
adult population and that suggests a positive relationship between glucose-based PD and 
weight change.  Additionally, the review will explain characteristics of each investigation 
that have influenced our project, aiding in the generation of our hypothesis and the design 
of our study methodology.  Table 1 summarizes key findings in this section of the 
literature review, in the order in which they appear in the section’s text. 
A 1999 cross-sectional study by Park et al. found the percentage of ideal body 
weight in its study population to be higher in PD patients than HD patients.1 This study 
raises the question of whether or not systemic glucose absorption or some other aspect of 
PD therapy causes PD patients to have more body weight than HD patients.  However, as 
 14 
the study is cross sectional, it does not establish causality between PD and weight change 
in its population.   
A 2001 study performed in Japan observed a cohort of 35 adult patients 
undergoing PD therapy, and performed multifrequency bio impedance analysis (to 
measure various body composition parameters) both at the start of the investigation and 
after one year of observation.2 The study found that 9 patients’ body weights increased by 
more than 3kg.2 The study concluded that in those patients whose body weight increased 
over the year, it was predominantly due to an increase in body fat.2 
A 2001 retrospective chart review by Jolly et al. found that 8 of 114 PD patients 
gained greater than 10kg during two years of PD.3 These 8 patients gained an average of 
13.1kg over this time period.3 A longitudinal observational study in 2000 showed an 
increase in total body fat mass and truncal fat mass over the course of PD therapy.4 A 
2008 retrospective study examined 195 incident adult PD patients (patients starting PD 
therapy for the first time) for Metabolic Syndrome and its components.5 The study found 
that BMI correlated with both duration of PD therapy and dialysate glucose.5 
A 1997 study by Heimburger found that over the first 12 months of PD, a cohort 
of 16 PD patients experienced a significant increase in body fat.6 The exact 
measurements of percentage of body fat were 19 with a standard deviation of 1.5 kg at 
the start of PD and 25.1 with SD of 2.2 kg after 12 months of PD therapy.6 Not only did 
these findings help us to generate our hypothesis, but also aided in the formulation of our 
study’s 12 month follow-up time. 
A 1992 study by Diaz-Buxo and Burgess found a statistically significant trend in 
weight gain during the first 17 months of peritoneal dialysis, which was followed by a 
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downtrend in weight change.7 The researchers examined a total of 100 peritoneal dialysis 
patients for this study, for a total time course of 36 months.7 Over the first 17 months of 
PD therapy, the mean weight gain of the cohort was found to be 6.41kg (about a 6.4% 
increase) with a SD of 8.36kg and a p value of less than 0.01.7 From 17 months to the end 
of the study (36 months), a downtrend in weight change was observed, and a mean 
weight change slightly less than 5% increase from baseline was reported.  Over the 
course of the study, there was a mean weight gain observed in PD patients with a steady 
uptrend in weight and a peak in weight gain at 17 months. 
A 1998 study by Fernstrom et al. prospectively followed 12 CAPD patients, and 
found that body weight increased over the course of the study, from 67.1kg to 68.4kg, but 
that this change was not significant (p= 0.20).8 However, the researchers found a 
significant increase of 22.8% in intra-abdominal fat area (p= 0.02), after a mean of 7.2 
months of CAPD.8 The authors also note that a statistically significant relationship 
between intra-peritoneal glucose absorption and body composition parameters measured 
in this study was not found.8 The authors recognize that due to small sample size, their 
study may not have had adequate power to detect a significant body weight change or 
correlation between glucose load and body composition measurements.8 Our proposed 
study will consider these limitations, and use an increased sample size as well as a 
historical comparison group, to better detect potential changes in body weight. 
Some of the previous studies we reviewed compared PD patients to HD patients 
in the adult population.  A 2011 study by Pellicano et al. examined a prospective cohort 
of 46 adults and found that the 17 patients of the cohort who were treated with peritoneal 
dialysis had a significantly increased gain in visceral fat, compared to the patients treated 
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with HD.9 A 2001 prospective cohort consisting of new adult dialysis patients (both PD 
and HD) found that PD was associated with body fat increase, with no increase in lean 
body mass.10 The researchers also found that PD patients had more moderate to severe 
loss of appetite, compared to HD patients.10 They also found HD patients to have a 
healthier nutritional status compared to PD patients.10 This study looked at changes in 
BMI over a two year time period.  They found that BMI increased in both PD and HD 
patients, however this increase was statistically significant only in PD patients and not in 
HD patients.10 They also found a significantly greater increase in body fat in the PD 
group.10 These results demonstrate the need and feasibility of examining similar 
parameters in children, as we plan to do in our study.   
A 2010 study by Cho et al. utilized a cohort of adult patients using icodextrin (a 
high molecular weight glucose polymer, leading to less absorption across the peritoneal 
membrane) as an osmotic agent in their PD therapy, and compared body composition 
changes to a cohort just using glucose as the PD osmotic agent.  This study examined a 
total of 75 incident PD patients over 36 months showed that the majority (78%) of weight 
gain over the study period occurred during the first year of PD.11 They also found that of 
the weight gained over the first year of PD, 88% was due to fat.11 The study compared an 
icodextrin group (36 patients) to a non-icodextrin group (39 patients), and found a greater 
glucose absorption across the peritoneal membrane, as well as larger changes in body 
weight, fat mass, visceral fat area, and waist/hip ratio, in the non-icodextrin group.11 This 
study concluded that use of icodextrin may lead to less weight and fat gain compared to 
glucose based PD.11 It adds to the knowledge base about the relationship in question 
because it suggests a possible association of glucose-based PD and weight gain.  
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Icodextrin-based dialysate is not an option for comparison in our study, as it’s current 
usage in once-daily long dwells for increased control of fluid removal during dialysis 
does not allow for it to replace glucose-based dialysate use in pediatric patients.12  
 
     Figure 1. Cho et al.’s Data of Mean Weight Change after 36 months of PD11 
 
A 2008 study by Wu et al. exclusively utilized PD patients in its cohort and 
examined the metabolic and peritoneal membrane effects of PD.  The study divided 
participants into groups based on their average dialysate glucose concentration during the 
first 6 months of PD therapy (low, medium, and high glucose load).13 They found a 
higher glucose load during this period to be associated with lower serum albumin, 
diabetes mellitus, lower residual renal function (RRF), and a worse survival prediction.13 
Although the primary outcome of this study was not weight gain itself, it indicates that 
increased exposure to glucose increases the risk of poorer outcomes, and that 
understanding the relationship of peritoneal dialysis to weight gain in pediatric patients is 
needed.  
 A 2012 study performed by Wu et al. examined long-term glucose exposure due 
to PD and its effect on patient outcomes.  The study recruited 173 patients, and evaluated 























glucose concentration is associated with both higher risk of technique failure and higher 
rate of mortality.14 In turn, they found lower glucose exposure associated with better 
technique outcome.14 Additionally, a five-year retrospective cohort study published by 
the same researchers in 2010 indicated that high BMI and DM were associated with the 
use of higher dialysate glucose concentrations in PD patients during the first three years 
of PD.15 The study calculated annual glucose weight and volume of dialysate to 
determine glucose load in its subjects.15 The study concluded that higher BMI and DM 
were factors that influenced the need to use higher glucose dialysate concentrations15, 
which is a relationship in the opposite direction of the relationship we plan to study in 
pediatric patients, but demonstrates an association between the two variables. 
 A 2011 prospective study by Choi et al. found that in a cohort of 60 adult patients, 
PD was associated with weight gain during the first 6 months of the therapy.16 Using 
body composition analysis, they determined that during this time period, subjects gained 
both visceral and subcutaneous fat.16 Although total weight was found to increase during 
the entire 12 month study period, when bioelectric impedance analysis and computed 
tomogram were used to evaluate body composition, visceral and subcutaneous fat 
increased during the first 6 months but both decreased during the second 6 months.  The 
researchers also found that low fat mass at baseline was associated with a greater increase 
in fat mass over the study period.16 This study is similar to ours in their examination of 
change in body mass during PD therapy and use of different cohorts of PD patients, 
however we will look at a different population (children) and will include different 
outcomes.  We will not measure different types of fat, but will be examining weight 
change.  
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A 2005 study by Jakic et al. examined a cohort of 40 adult patients receiving 
peritoneal dialysis, and found that although body weight gain was observed in all patients 
on PD therapy over the study time period of 36 months, there was no statistically 
significant correlation between the body weight gain and glucose absorption from the 
peritoneal dialysate.17 The primary outcome of the study was body weight change.17 
Initial body weight increased by 7.9kg (or 11.62%) with a SD of 4.9kg at 12 months.17 
Initial body weight increased by 11kg (or 16.18%) with a SD of 5kg at the end of the 36 
month study.17 Even with lack of a significant correlation between weight gain and 
glucose absorption, these results strongly suggest the need for our study, which will 
examine weight change in children on PD. 
 
Figure 2: Jakic et al.’s Data of Body Weight Change during PD17 
 
A 2004 retrospective study by Pennell et al. looked at 56 adult PD patients, and 
compared metabolic parameters before initiation of PD to after initiating PD.18 Subjects 
recruited were required to be on PD for at least 6 months, to allow of adequate data 
collection by investigators.  They found that after the initiation of PD, a measurement that 
they defined as “excessive” weight gain occurred in 20% (11 of the total 56 patients in 
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researchers defined “excessive” weight gain as 10-24% increase in body weight.18 They 
also found that all lipid levels except HDL increased significantly after initiation of PD 
therapy.18 Additionally, the occurrence of one or more of the following three factors, 
hyperlipidemia, hyperglycemia, and obesity, was found in 84% of the study 
participants.18 This study shows that the initiation of peritoneal dialysis is associated with 
weight gain and other metabolic risk factors, and suggesting the need for our study.  
A 2015 study by Kim et al. investigated weight gain and its relationship with 
adverse effects such as inflammation, DM, and rapid decrease in RRF over the first year 
of PD in adult patients.  Obesity prevalence was 38.5% at the start of PD, and increased 
to 46.6% after one year of PD therapy.19 The study found a mean 3% increase in body 
weight over the first year of PD.19 It also found that increase in body weight was 
associated with an increased rate of RRF decline, and an increased risk of RRF loss.19 
The study concludes that in peritoneal dialysis patients who use glucose-based dialysate, 
weight gain is a significant risk due to dialysate glucose absorption and increase in 
uremic effects.19 
This same 2015 study by Kim et al. found a significant association between 
excess body weight gain and increased glucose absorption from the dialysate.19 However, 
the researchers were not able to establish a causal relationship between body weight 
change and systemic glucose absorption as their measurement of body weight did not 
differentiate weight due to retained volume.19 This study supports a positive relationship 
(although not causal) between weight change and PD therapy in the adult population, 
further amplifying the need to study this potential relationship in the pediatric population. 
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Table 1: Summary of Literature in Adult Population; Part One 
Author Date Key Findings 
Park et al. 1999 Higher percent body weight in PD versus HD 
patients1 
Kanazawa et al. 2001 Weight gain greater than 3kg in 9 of 35 patients, 
after one year of PD2  
Jolly et al. 2001 Weight gain greater than 10kg in 8 of 114 patients 
after two years of PD3 
Stenvinkel et al. 2000 Longitudinal observation of PD patients showed 
increased total fat mass and increased truncal fat 
mass4 
Jiang et al. 2008 Increased BMI associated with increased duration of 
PD and increased dialysate glucose usage5 
Heimburger et al. 1997 Body fat increased significantly over 1st 12 months 
of PD6 
Diaz-Buxo and Burgess 1992 Statistically significant weight gain found after first 
17 months of PD7  
Fernstrom et al. 1998 Non-significant body weight increase in PD patients, 
significant increase in intra-abdominal fat area after 
7.2 months PD8 
Pellicano et al.  More visceral fat gain with PD therapy, compared to 
HD therapy9 
Jager et al. 2001 Significantly greater increase in body fat in PD 
patients, compared to HD patients10 
Cho et al. 2010 Non-icodextrin group showed greater change in 
body weight, fat mass, visceral fat area11 
Wu et al. 2008 Higher peritoneal glucose load associated with 
Diabetes Mellitus, lower RRT, worse survival in PD 
patients13 
Wu et al. 2012 Higher peritoneal glucose load associated with 
technique failure and increased mortality in PD 
patients14 
Wu et al. 2010 High BMI and Diabetes Mellitus each associated 
with greater dialysate glucose usage15 
Choi et al. 2011 PD use associated with weight gain during first 6 
months therapy16 
Jakic et al. 2005 Significant body weight increase after 12 months 
and after 36 months of PD17  
Pennell et al. 2004 10-24% body weight increase in 11 of 56 patients 
during 6 months of PD18 
Kim et al. 2015 Increase in obesity prevalence after one year PD; 
Significant association between body weight gain 
and increased glucose absorption from dialysate19 
 
 
PD Use and Weight Change in Adult Patients:  Part Two 
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As it is now evident, there is an existing body of research to suggest a positive 
association between PD and weight change in the adult population.  Our proposed study 
will utilize similar methods to investigate the relationship between PD and weight 
change, which will be discussed in more detail later in this chapter as well as in Chapter 
3.  Our study will retain its novelty in the fact that we will be studying a pediatric 
population rather than an adult population.  We will next discuss previous research in the 
adult population that does not support a positive association between PD and weight gain.   
A 1992 study by Saxenhofer compared body composition changes among PD 
patients to adult HD patients, and found no significant differences between the two 
dialysis modalities in regards to muscle mass/fat distribution changes.20 The researchers 
concluded that in their population, glucose load did not contribute to additional body 
composition changes (compared to HD patients).20 However, this study’s primary 
outcome differs from our primary outcome of weight change over time on PD.  
A 1996 study was performed in the adult population to determine if systemic 
glucose absorption from PD caused adverse effects (including obesity).  The results 
suggest that glucose absorption does not suppress appetite and does not cause obesity21.  
The researchers also found no difference in survival between those with higher calorie 
intake across the peritoneal membrane versus those with lower calorie intake across the 
peritoneal membrane21.  This study grouped its subjects based on calorie absorption 
across the peritoneal membrane (two groups, one above 6cal/kg and one below 
6cal/kg)21.  Our study will utilize different groupings of our cohort to better detect an 
association. 
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A 1988 study compared nutritional status of HD and PD patients, including body 
weight, and found no difference in the nutritional status between the two groups22.  The 
study utilized a small number of 16 PD patients, and compared this cohort to 32 HD 
patients.  Outcomes were measured in only 54% of patients22.  Our study will not utilize 
HD patients as a comparison, which will aid in reduction of confounders.  We will also 
utilize a larger sample size. 
 A 2008 study found body fat change in 45 PD patients, over a period of one year, 
to be highly variable.23 The study measured factors including body composition, 
nutritional status, and energy intake with 3-day food records.23 The study did not find an 
association between daily glucose absorption and body fat.23 However, they found that 
baseline BMI was the factor most associated with body fat gain.23 
 A 2012 study compared adult HD patients to adult PD patients and measured BMI 
change over a period of six years.24 They found that weight gain was less likely in PD 
patients, compared with HD patients.24 Our study will utilize different comparison 
groups, as well as a different population (pediatric population).  Our study will also 
utilize a shorter follow-up time, based on previous studies that show a positive 
relationship between PD and weight change occurring to the largest extent in the first 
year of PD therapy.7,11,16,19  
 A 2015 study by Ho et al. did not find a significant correlation between visceral 
fat area and glucose load in PD patients.25 However, our study will differ in that we will 
be exploring other independent variables such as age, in addition to glucose load, to 
evaluate weight change.  Additionally, Ho et al.’s study specifically measured visceral fat 
area, while our study will measure weight change in kilograms, to detect any possible 
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correlation with PD therapy.  Our study will also use a different population, pediatric 
patients.   
A 2014 study by Fan and Davenport found similar results.  They found that 
increased glucose load (as patients became anuric, and the need for a higher glucose 
dialysate concentration arose) was not associated with body fat gain.26 Our study will be 
looking at a different dependent variable (weight change in kg). We will recruit patients 
who are just beginning dialysis, regardless of their urine output.  Several studies that we 
reviewed that show a positive relationship between PD and weight gain show the biggest 
weight gain in the first 1-1.5 years.7,16,19 This study may not have been designed to detect 
an association between body fat gain and PD, as it did not start its follow-up period at the 
initiation of PD, as our study will. 
Table 2: Summary of Literature in Adult Population, Part Two 
Author Date Key Findings 
Saxenhofer et al. 1992 No significant difference in body composition 
between PD and HD patients20 
Davies et al. 1996 No association between obesity and peritoneal 
glucose absorption in PD patients21 
Marckmann 1998 No difference in body weight between PD and HD 
patients22 
Vasselai et al. 2008 No association between glucose absorption and 
body fat23 
Lievense et al. 2012 Weight gain less likely in PD, versus HD, patients 
after six year follow-up24 
Ho et al. 2015 No significant correlation between visceral fat area 
and glucose load in PD patients25 
Fan and Davenport 2014 No association between increased glucose load and 
body fat gain in PD patients26 
 
 
PD Use and Weight Change in Pediatric Patients  
 Compared to the adult population, less research has been performed in the 
pediatric population that explores the relationship between glucose-based PD and weight 
change.  The following section consists of a literature review of four investigations we 
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reviewed that suggest an association between these two variables.  Each study differs 
from our project in methodology and outcomes, however these studies have influenced 
both the generation of our hypothesis and methodology design in ways that will be 
discussed further in the following sections. 
A 2005 retrospective analysis by Hanevold et al. examined the prevalence of 
obesity in pediatric ESRD patients aged 2-17, and found that obese patients had been on 
dialysis for a longer period of time than non-obese patients.27 The main investigation of 
this study was transplant outcomes in obese versus non-obese children.  However, this 
study’s finding that obese patients had been on dialysis for a longer period of time helped 
us to generate our hypothesis, especially since it pertains to the pediatric population. 
 Results of a 1999 study by Schaefer et al. suggest a potential relationship between 
glucose-based PD therapy and weight gain in pediatric patients.28 The study utilized a 
prospective cohort design, with a population of 51 pediatric patients on peritoneal 
dialysis.  The cohort was followed for 18 months, and a statistically significant 
association between peritoneal transport and weight gain was found in the study 
population.28 Specifically, a faster rate of peritoneal creatinine equilibration (a measure of 
peritoneal membrane function in PD) and increased volume of glucose-based dialysate 
solution during dialysis were each associated with an increase in BMI.28 This study was 
used to generate our hypothesis.  We plan to use different independent variables than 
Schaefer et al. used, however our outcome variable will be change in weight (comparable 
to the outcome variables used by Schaefer et al.).  The parameters that will be measured 
in our study will aid in a better understanding of the relationship between glucose based 
PD and weight gain in pediatric patients.  Also, one of our independent variables will be 
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expected weight change without PD therapy, which will serve as a historical control 
group and will allow us to more accurately explore this relationship.   
A 2013 study by Bonthuis et al. investigated BMI changes in a cohort of 4474 
pediatric ESRD patients from 25 different countries, who were treated between the years 
of 1995 and 2010.29 BMI measurements were analyzed at the start of RRT (dialysis or 
transplant) and after 6-18 months of follow-up.29 The study demonstrated that after 
follow-up of 6-18 months, the prevalence of patients who were overweight and obese 
increased.29 The study also found that lower BMI at the start of RRT, older age at the 
start of RRT, longer time on dialysis, and starting RRT on PD (versus HD) were factors 
associated with a larger increase in BMI.29 Our proposed study will utilize similar 
variables, including starting BMI and age, and will exclusively study PD patients to 
better understand the relationship of PD therapy with BMI change in pediatric patients. 
A 2012 retrospective investigation by Watanabe et al. recruited 30 PD patients 
and measured various hemodynamic and anthropometric variables at the start of PD and 
after at least 6 months of PD therapy.30 Of note, the researchers found no statistically 
significant difference between initial and final z-scores (a statistical representation of a 
measurement in relation to the mean and standard deviation of a group of measurements) 
for patient weight.30 Although this result does not support a relationship between PD and 
weight change in pediatric patients, our study will utilize a historical comparison cohort 
to possibly more accurately detect a relationship between PD therapy and weight change. 
Table 3: Summary of Literature in Pediatric Population 
Author Date Key Findings 
Schaefer et al. 1999 Increased peritoneal glucose absorption associated 
with increase in BMI over 18 months of PD 
therapy28 
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Hanevold et al. 2005 Obese patients on dialysis longer than non-obese 
patients27 
Bonthuis et al. 2013 Starting RRT on PD (versus HD) associated with 
larger increase in BMI29 
Watanabe et al. 2012 No statistically significant difference in weight after 
PD duration of 6 months or greater30 
Methodology Review and Justification 
 
Study Design 
We will use a prospective cohort study design to explore the relationship between 
PD and weight change in children.  Dialysis prescription is based upon numerous factors, 
including residual renal function.  This said, it is both unethical and dangerous to 
manipulate a dialysis prescription for the purposes of a study, and we cannot utilize an 
experimental study design, or Randomized Control Trial (RCT).  Therefore, we will use 
an observational study design in the form of a prospective cohort.  Previous research 
shows that weight gain predominately occurs during the first year of dialysis initiation; 
therefore a prospective design with a one year follow-up period was chosen.7,11,16,19  
Population and Setting 
We plan to recruit and examine a population aged 2 through 17 years old to 
investigate the relationship between PD and weight change.  An investigation by Ku et al. 
used a population aged 2-19 for retrospective analysis of BMI and outcomes, and found 
that higher BMI was associated with higher risk of death and lower rate of transplant.31 
As this is one of the previously reviewed studies that we are using to justify the necessity 
of our own study, it is fitting that our population age range be similar.  Additionally, a 
study by Hanevold et al. that contributed to the generation of our hypothesis examined 
the risks of obesity on renal transplant, and used a population of patients aged 2-17 years 
old.27 Using a similar age group to that used in prior pediatric studies allows better 
comparison of our results to published data.  Also, a lower limit of two years was decided 
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because CDC growth charts (which we will use to form a historical control group) pertain 
to children age 2-20.32 An upper limit of 17 years old will improve the generalizability of 
our results to a pediatric ESRD population, as renal transplant listings consider patients 
18 years and older as adults, leading to different transplant eligibility criteria. 
We plan to conduct data collection in the outpatient dialysis clinic setting, where 
patients will attend regular monthly appointments while undergoing PD therapy at home.  
Our measurements (specifically, weight in kg) will be done routinely at each follow-up 
appointment whether or not a patient is enrolled in our study, which supports the 
feasibility of our data collection methods.   
Recruitment Methods 
Patients will be recruited from the Midwest Pediatric Nephrology Consortium, a 
collaborative group that facilitates recruitment of pediatric patients into pediatric 
nephrology clinical research.  This consortium recruits patients from its 57 member 
centers from various areas in the United States into many different types of pediatric 
nephrology research projects, including multi-center studies.  Our study will be open for 
recruitment patients from all member centers of the consortium, as well as the Yale 
Department of Pediatric Nephrology.  Inclusion criteria will include age 2 through 17 
years old, and access to prior health records of at least twelve months, as this will be 
needed to estimate expected weight change and form our study’s historical control 
group.  Exclusion criteria will consist of prior use of dialysis therapy (peritoneal dialysis 
or hemodialysis), to decrease possible introduction of confounding variables.   
Variables  
The primary outcome variable will be weight change, measured in kilograms.  
Kim et al.’s 2015 study investigated weight gain and its relationship with adverse effects 
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over the first year of PD in adult patients.  The study concluded that in adult PD patients 
who use glucose-based dialysate, weight gain is a significant risk due to dialysate glucose 
absorption,19 justifying the need for use of our primary outcome variable of weight 
change.  Further justification for use of this outcome variable includes the 2005 study by 
Jakic et al., which was described earlier in this chapter, and which used a primary 
outcome of body weight change.17  
The parameters that will be measured in our study will aid in a better 
understanding of the relationship between glucose based PD and weight change in 
pediatric patients.  Our use of a matched control variable of expected weight change 
without PD therapy will aid in a greater understanding of how glucose based PD is 
associated with weight change.  It is unethical to use a placebo group in our study, or a 
control group of non-PD ESRD children.  We will be using a historical control group 
using Centers for Disease Control (CDC) growth charts to estimate expected weight 
change in kg at our follow-up measurement times.32 Additionally, we will collect data 
from participants’ prior health records, recording their weight in kg from 12 months prior 
to dialysis initiation, and use this as a self-control group that will be compared to the 
actual weight change in the cohort after 12 months of PD therapy.  The two control 
groups that will each be compared to the actual weight gain during 12 months of dialysis 
are as follows: 
1. Predicted weight gain according to CDC growth curves, from the patient’s 
baseline weight at the initiation of dialysis 
2. Weight change retrospectively reviewed and recorded from patient’s prior 
health records, over the course of 12 months prior to initiation of dialysis 
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The use of a historical control group is a method that has been used in past studies 
in which it is unethical to use a placebo/non-treatment group due to standard of care 
guidelines and past research.  A 2009 study examined survival benefits of treatment with 
alglucosidase alfa (an enzyme replacement) in children with a congenital disorder.33 They 
used a historical control group using retrospective chart analysis because use of their 
intervention was the current standard of care, making the use of a placebo group 
unethical.33 This method has also been used in studies that examine pediatric growth 
parameters as outcome variables, as our study will utilize.  For example, a 2015 
prospective randomized study used a historical control group of adolescents as a 
comparison to the study’s intervention group receiving growth hormone therapy.34 The 
study’s control group was matched for puberty and past growth data, and the primary 
outcome of the study was change in height.34 
   Additionally, this method was used in a study investigating body composition 
changes over time in PD patients.  A 1998 study by Johansson et al. prospectively 
examined 60 adult PD patients, and found that within the group, individual changes in 
body weight correlated significantly with individual body fat changes.  The researchers 
compared observed values of body composition parameters (including body fat and body 
weight) to predicted values generated from local population studies.35   
Our secondary analysis divides our cohort into groups based on: 
1. Dialysate dextrose concentration used  
2. Starting BMI 
3. Starting age 
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These stratifications will help us to better understand our research question.  We have 
chosen to group based on dialysate dextrose (a glucose isomer) content, rather than 
dialysate volume, to more accurately detect a relationship between peritoneal glucose 
load and weight change (versus dialysate presence in general). 
Our review of the literature has shown a possible association between starting 
BMI and weight change during PD therapy.  A study by Choi et al. found that subjects 
with a lower baseline fat mass at the start of PD demonstrate greater gain in fat mass over 
the first six months of PD therapy.16 A 2008 study by Vasselai et al. found that baseline 
BMI was associated with body fat gain in PD patients.23 The reviewed 2013 study by 
Bonthuis et al. found that, in the pediatric population, a lower starting BMI is associated 
with larger BMI increase during RRT.29 We have chosen to use starting BMI as one of 
our independent variables, to assess a possible association between starting BMI and 
weight change during the first 12 months of PD.  
Review of the literature also suggests a potential relationship between starting age 
and weight change during PD therapy.  The pediatric cohort investigated by Bonthuis et 
al., in addition to the results mentioned in the above paragraph, demonstrated a larger 
increase in BMI (after follow-up of 6-18 months) with older age at the start of RRT.29 
Timing of recruitment, data collection, and follow-up 
 The data collection of our study will occur over a period of 24 months.  We will 
recruit patients on a rolling basis during the first 12 months of our study’s two-year data 
collection period (as it will allow completion of data collection within two years time).  
Our follow-up time for each subject will be 12 months. 
We have chosen a 12-month follow-up period because several studies that we 
reviewed demonstrate a positive relationship between PD and weight gain indicate the 
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largest amount of weight gain to occur in the first 1-1.5 years of PD therapy.7,11,16,19 One 
of these studies examined incident PD patients over 36 months and found that the 
majority of weight gain over the total 36 months (78%) occurred during the first year of 
PD.11 It was also found that 88% of the total weight gained by patients during the first 
year of the study was due to gain of fat mass.11 After reviewing this information, it was 
decided that 12 months is an adequate follow-up period to detect any weight change after 
the start of PD.  
Additionally, it has been demonstrated that trans peritoneal glucose absorption 
during dialysis remains relatively constant over time.36 These data were collected from 
long term follow-up of six years.36 This said, one year will be a sufficient time period to 
detect what percentage of the pediatric population of the study will experience a weight 
gain with dialysis therapy.36 
Our decision to use a 12 month follow-up time is supported by the United States 
Renal Data System’s most recent data, which state that incident (first time) dialysis 
patients aged 0-21 years old have a median wait time to transplant of 1.01 years from 
when they are listed for transplant.37 This supports the notion that the majority of our 
study population will be able to complete the full study follow-up period of 12 months 
before switching RRT method to transplantation.   
Statistical Methods 
Descriptive data that will be measured in the cohort represent characteristics that 
may be related to our outcome variables, and will be measured at the start of data 
collection and monthly for the 12-month follow-up period.  These characteristics are 
listed in Chapter 3.  Because our primary outcome utilizes historical control groups, we 
will use means and standard deviations to describe these characteristics of the cohort.  In 
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our secondary analyses, in which we divide the cohort into two groups based on three 
covariates (starting BMI, starting age, and dialysate glucose concentration prescribed), 
we will utilize ANOVA to compare outcome variables.  Appropriate comparison tests 
will be utilized at the end of data collection to compare the characteristics used to 
describe the sample, based on whether the data is normally or non-normally distributed. 
 The primary outcome of our study, mean weight change, measured monthly over 
the first 12 months of PD therapy, is a continuous variable.  We will use a two-sided 
analysis to enable detection of both weight increase and weight decrease in the cohort.  
Therefore, we will use the paired student t-test to compare primary outcomes in patients 
undergoing glucose-based PD therapy with the historical control group consisting of 
numerical values of expected weight change in the absence of PD therapy (generated 
with CDC growth charts).  Additionally, we will use the paired t-test to compare weight 
change over the course of 12 months of PD therapy to weight change generated from the 
cohort’s prior records of weight measurements from the 12 months leading up to 
initiation of PD therapy.   
In our secondary analysis, the outcome of mean weight change is also a 
continuous variable (difference between actual and expected weight change over the first 
12 months of PD therapy, measured in kg).  Therefore, because the cohort will be divided 
into two groups during our secondary analyses, we will utilize the paired t-test to 
compare secondary outcomes.  We will then use multiple regression analysis to evaluate 
relationships between the groupings of our secondary analysis.    
Sample Size 
 It is now evident that the relationship between PD and weight change has been 
studied to a greater extent in the adult population, versus the pediatric population.  This 
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said, the results of our literature review did not allow for an estimation of effect size of 
change in kg over one year of PD in pediatric patients.   
Effect sizes from previous study designs in the adult population, which have been 
discussed in further detail in the first section of this chapter, were utilized.  For example, 
Jakic et al.’s 2005 study found an effect size of 7.9kg (mean change from baseline) with a 
standard deviation of 4.9, after 12 months of PD therapy17.   
However, we have decided to utilize the effect size found in Cho et al.’s 2010 
study, as the mean change in baseline demonstrated in this study was 3.59 kg in patients 
undergoing the first 12 months of glucose dialysate PD11, a smaller mean change in 
baseline compared to Jakic et al.’s study.  Because our study is using a novel population 
and design, we attempt to ensure the greatest chance of detecting a mean change from 
baseline in our own study by using the smaller effect size to calculate the required sample 
size.  Cho et al.’s study design is very similar to our methodology in that researchers 
investigated weight change, in kg, of patients on glucose-based PD.  They found that 
their sample (both the glucose dialysate group and the icodextrin dialysate group) gained 
an average 2.5 kg with a standard deviation of 5kg during the first 12 months of PD, 
which is the follow-up period of our study11.  Specifically, the non-icodextrin group 
(glucose-based PD, the exposure being studied in our investigation) gained 3.59 kg in the 
first year of CAPD therapy.  Our study is not utilizing an icodextrin group.  We have 
calculated two sample sizes in the planning of our methodology, using effect sizes of 
2.5kg and 3.59kg (weight change), with a standard deviation of 5kg. 
 PS: Power and Sample Size Calculation version 3.1.2 software was used to 
calculate our study’s sample size.  Using an effect size of 2.5, a standard deviation of 5, 
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an alpha value of 0.05 and power of 80%, a sample size of 33 was calculated (Appendix 
B).  Using an effect size of 3.59, with the same alpha value, power, and standard 
deviation, the software calculated a sample size of 17 (Appendix B).  Ideally, we would 
like to recruit 33 participants per grouping, to err on the side of modesty in our study 
design.  Because several of our study’s secondary analyses will involve division of the 
cohort into two groups (based on the three cofactors of starting BMI, dialysate glucose 
concentration, and baseline age), we plan to recruit a minimum of 66 subjects into our 
study (double the raw sample size of 33).  However, it is noted that a sample size of 17 
(total of 34 when the cohort is divided into two groups) is estimated as sufficient to detect 
weight change (kg) from baseline, after one year of glucose-based dialysate PD therapy. 
 The most recent data from the United States Renal Data System indicate that in 
2013, there were 367 incident cases of pediatric patients starting PD therapy.  This 
equates to an incidence rate of 3.9 per million per year.  The data also demonstrate that 
the point prevalence as well as incidence of pediatric patients on PD has remained 
relatively steady from the years 1996 to 2013.  When considering the feasibility of our 
sample size, we extrapolate from this data that approximately 360-370 pediatric patients 
will initiate PD therapy in the United States each year that our study takes place.37 
 Another consideration we analyzed while assessing the feasibility of our sample 
size was the wait time of pediatric patients once they have been listed for transplant (as 
this is the preferred method of RRT in the pediatric ESRD population.  As mentioned 
previously, incident dialysis patients aged 0-21 spend a median time of 1.01 years 
waiting for a kidney transplant (on dialysis in the meantime).37 The fact that the median 
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time to transplant is just over one year supports the feasibility of our study to gain 
adequate data from a sufficient sample size over the entire study’s time period.  
Loss to follow up is unlikely in our study, as patients are undergoing dialysis 
therapy for kidney failure, and the measurements we will use in our study are routinely 
taken at appointments.  As this study is an observational study, and the exposure will not 
be manipulated by our study, we don’t anticipate any significant loss to follow up.  We 
expect the predominant reasons why some patients will not be able to finish the follow-up 
period are changing method of dialysis (to HD), transplant, or death.  A study by Tsai et 
al. prospectively examined a cohort of pediatric PD patients, and found a 96.55% survival 
rate after two years of PD therapy38.  Additionally, they found that those PD patients who 
switched to HD at some point after initiating PD, (27.5%) remained on PD for a mean 
time of 3.98 years with a standard deviation of 2.14 years.38 Combined with the 
previously discussed data that incident dialysis patients spend a median of 1.01 years 
waiting for a kidney transplant, we anticipate that the majority of our recruited cohort 
will remain on PD and therefore in our study for the full follow-up time of 12 months.  
However, it is likely that a percentage of patients will not be able to complete the study 
for the previously mentioned reasons.  Recruiting a minimum sample size of 66 will 
allow for as much as a 48% dropout rate (32 of the 66 subjects can drop out or be lost to 
follow up) for our study to maintain adequate power to detect difference in outcome in 
our cohort, as the above mentioned calculations indicate recruitment of a total of 34 
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 We will conduct a prospective, observational, analytical, multicenter study to 
examine the relationship of PD therapy and other baseline characteristics with the 
primary outcome variable of mean weight change.  All recruited patients will receive 
glucose-based PD therapy, and will be followed for a total follow-up period of 12 
months.  Time zero (the start of the study) will be the time of initiation of glucose based 
PD therapy.  All variables will be measured at initiation of PD, 6 months after starting 
PD, and 12 months after starting PD.  The study setting will be an outpatient pediatric 
dialysis clinic.  
Population and Sampling 
 
The study population will consist of pediatric ESRD patients aged 2-17 who are 
initiating PD therapy.  Subjects will be recruited from the Midwest Pediatric Nephrology 
Consortium, a common location used to recruit patients into pediatric nephrology clinical 
research.  We will use a non-random, convenience, consecutive sampling method.  
Inclusion criteria will include age 2 through 17 years old, and access to prior health 
records of at least twelve months prior to recruitment into the study.  These records will 
be used to form one of our historical control groups.  Exclusion criteria will consist of 
prior use of dialysis therapy (peritoneal dialysis or hemodialysis).     
Variable Measures 
 
 Baseline characteristics will be measured at the start of the study as well as 
monthly (when applicable) in all subjects, and then further divided by grouping for the 
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secondary analysis.  The characteristics that will be described at the start of the study 
include: 
1. Age  
2. Gender  
3. Race 
4. Primary diagnosis leading to ESRD  
5. Urine output 
6. Prescription of erythropoietin (yes or no) 
7. Prescription of growth hormone (yes or no) 
8. Peritoneal Equilibration Test (PET) results  
9. Daily volume of PD therapy 
10. Laboratory values obtained from blood sample (serum albumin, lipid profile, and 
normalized protein catabolic rate) 
11. Appetite (categorized into poor, average, good) 
12. Physical activity level (categorized into light, moderate, and strenuous) 
13. Socioeconomic status (categorized into poverty, low income, middle class, and 
upper class) 
The characteristics that will then be measured monthly (may change throughout the 12 
month follow-up period) include: 
1. Daily urine output 
2. Prescription of erythropoietin 
3. Prescription of growth hormone 
4. Daily volume PD dialysate 
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5. Appetite 
6. Physical activity level 
 As stated above, the dependent variable and primary outcome of our study is 
mean weight change after 12 months of glucose based PD therapy.  Our study will 
measure various independent variables to analyze their relationship with the primary 
outcome, mean weight change, a continuous variable.  The first independent variable we 
will measure is the use of glucose based PD therapy.  We will analyze this relationship 
using the expected weight change (at 12 months after the start of PD) in each recruited 
patient.  This expected weight change will be calculated using the CDC’s pediatric 
weight-for-age growth curves (Appendix A), and will serve as the outcome for the 
control (non-exposed) group.  The measured weight change over the course of 12 months 
of PD therapy will serve as the outcome for the experimental (exposed) group.  
Additionally, to further explore our research question, participants’ prior health records 
dating 12 months prior to initiation of dialysis will be used as a second control group.  
We will gather the historical 12-month weight change immediately prior to dialysis and 
compare this to monthly weight change during the first 12 months of dialysis.  Therefore, 
for our primary analysis, patients will serve as their own controls.   
 Our secondary analysis will investigate the relationship of three cofactors; 
dialysate dextrose concentration, starting BMI, and starting age; to weight change over 
the course of 12 months on glucose based PD therapy.  In this secondary analysis the 
outcome of weight change will be measured as the difference between observed (actual) 
weight change and expected weight change.  Expected weight change will be determined 
by CDC growth curves (Appendix A), which will be the same measurements used to 
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generate the historical control group of the primary analysis.  This will decrease the risk 
of our results being confounded by factors such as differing rates of growth based on 
developmental stage of the child, as well as lessen the risk of our results being due to 
normal growth of the child.  The equation used to calculate the secondary outcome of 
weight change is as follows, and will be calculated monthly for each participant: 
(Observed weight change during PD therapy, in kg) – (expected weight change from 
baseline for corresponding point in time, using CDC growth chart, in kg) 
For our analysis of exposure to dialysate glucose, we will divide our cohort of 
pediatric PD patients into two groups according to dextrose concentration of the 
prescribed dialysate: 
1. Less than 2.5% dextrose concentration 
2. Greater than 2.5% dextrose concentration 
  We will then measure actual and expected weight change and use the above 
equation to obtain our outcome measurements.  We will then compare the outcome 
variable measured monthly for the 12-month follow-up period between the two dextrose 
groups.  If a participant changes dialysis dextrose prescription during the study, we will 
keep them in the dextrose group in which they started dialysis therapy.   
 We will also group the cohort by initial BMI to detect if this independent variable 
has any relationship with weight change.  We will group patients as follows:  
1. Below 25 kg/square meters 
2. Greater than or equal to 25 kg/square meters 
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We will then measure actual and expected weight change, and use the above equation to 
arrive at our secondary outcome measurements.  Next, we will compare outcome 
variables between the two groups. 
 We will also group patients based on age to examine whether this independent 
variable is associated with weight change.  We will group patients using the age ranges as 
follows:  
1. 2-11 years old 
2. 12-17 years old 
Next, we will compare outcome measurements (obtained from above equation) between 
the two groups. 
Statistical Analysis 
 
We will describe baseline characteristics of the cohort of our primary outcome 
with means and standard deviations.  At the end of data collection, we will compare 
baseline characteristics among the secondary outcome groupings using appropriate 
comparison tests depending on how the characteristics are distributed (normally or non-
normally distributed).   
We will use a two-tailed analysis to compare all outcome measurements (both 
primary and secondary), with a significance level (p-value) of less than or equal to 0.05.  
To compare outcomes in our primary analysis, which involves comparison of weight 
change from two groups (PD therapy and the historical control group of no PD therapy), 
we will utilize the paired student t-test.  Additionally, patient records of weight change 
over the 12 months prior to PD initiation will serve as a second control group, allowing 
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comparison of weight change 12 months prior to dialysis and for the first 12 months of 
dialysis, using the paired t-test.   
In our secondary analyses (division of the cohort into two groups by glucose 
prescription, age, and initial BMI range), we will utilize the paired t-test testing to 
compare outcome (weight change) between the corresponding groups, as these divisions 
of the cohort will result in two groups that will be compared in regards to the outcome of 
excess weight change.  
We will also utilize multivariate regression analysis in our secondary analysis to 
test relationships between monthly measurements of weight change and other measured 
characteristics for each group of our secondary analysis. 
Sample Size Calculation 
 
The sample size is calculated using PS: Power and Sample Size Calculation 
version 3.1.2.  Our study will be powered to 0.8, paired, with an alpha level of 0.05.  An 
estimated effect size of 2.5 mean change from baseline weight (in kg), with a standard 
deviation of 5, was used to calculate a sample size of 33.  Several of our secondary 
analyses will divide the cohort into two groups, and we will recruit at least two times this 
number which equates 66 patients in total (Appendix B). 
Recruitment 
 
 Participants will be recruited through Yale New Haven Hospital’s Pediatric 
Nephrology department, as well as all member centers of the Midwest Pediatric 
Nephrology Consortium using a nonrandom, convenience, and consecutive sampling 
method.  All incident cases of PD aged 2-17 who are initiating glucose dialysate PD 
therapy at participating centers during the first 12 months of our investigation will be 
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asked to participate in the study.  Patients who have been on a previous method of 
dialysis (including both peritoneal dialysis and hemodialysis) in the past will be excluded 
from participation.  Patients will be informed of what measurements will be taken for the 
purposes of this study, and will sign a the appropriate consent forms in order to 
participate, which are described later in this chapter.  
Confidentiality and Safety 
 
 The study will be approved by Yale Human Investigation Committee (HIC).  
Employees of the study will complete HIPPA training and adhere by HIPAA regulations 
to ensure the confidentiality of our recruited patients.  Identifying information will be 
removed from any public release of data gained from the study.  Parents/legal guardians 
of minors (children under 18) will sign informed consent and HIPAA authorization 
(Parental Compound Authorization) before their child will be enrolled in this study.  
Children 7-17 years old will also sign an assent form specific to their age group (one for 
7-12 years old, one for 12-17 years old), per the Yale University Human Investigation 
Committee Pediatric Protocol.1 Appendices C-E include copies these of consent/assent 
forms. 
 Patient’s names will be replaced with a numerical code when storing their 
information and measurements for the purposes of this study.  Each participating dialysis 
center/medical center will keep any paper documents/information pertaining to the study 
in a locked cabinet.  All information reviewed and used in this study will be treated as 
protected health information.  Any electronic information will be viewed and stored on an 
encrypted device according to HIPPA regulations.  
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 To ensure the safety of all study participants, follow-up will take place in an 
outpatient dialysis clinic, and patients’ nephrologists will manage their dialysis 
prescription and efficacy.  
Data Collection and Follow up 
 
 Data will be collected at patients’ initial dialysis appointment, and monthly at 
follow-up appointments for 12 months after starting dialysis.  Weight will be routinely 
measured at all appointments, and will be extracted from the patient’s chart.  Data 
collection forms will be stored in the locked cabinet designated for our study (Appendix 
F). 
Considering the observational nature of our study, independent variables will not 
be manipulated or assigned.  Each patient’s nephrologist will manage their dialysis 
prescription without any consideration that they are in the study.  If a patient stops 
dialysis, switches dialysis method (to hemodialysis), or receives a kidney transplant 
during the study, they will be removed from the study as they will be unable to complete 
the 12-month follow-up period of data collection.   
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Chapter 4- Conclusion  
 
Advantages and Disadvantages 
 
Our study aims to provide the field of pediatric nephrology with insight into the 
relationship between PD prescription and weight change in pediatric patients.  This 
information will fill a gap in the literature surrounding this topic, as well as contribute to 
understanding of the physiologic response of pediatric patients exposed to peritoneal 
glucose load.  PD’s effect on patient weight is a relationship that if better understood, 
could lead to innovations in dialysis prescription to improve outcomes in pediatric 
patients with ESRD, as well as changes to the current standard of care.  Additionally, a 
more concrete understanding of the effects of peritoneal glucose load in regards to weight 
change could stimulate further research in the pediatric population pertaining to 
interventions or alternatives to avoid weight change that is not explained by normal 
growth.  With the gold standard of treating ESRD in children being renal transplantation, 
one that gives the child the best possible quality of life and survival, the relationship of 
glucose-based PD use in children and BMI is a relationship that needs to be investigated 
to improve treatment outcomes in this population.   
 Advantageous qualities of our study include use of a historical, individualized 
control group.  This reduces confounders that would be introduced through the use of a 
healthy control group not on PD therapy, or a group of pediatric ESRD patients on HD 
therapy.  This allows insight into the relationship in question without introducing 
confounders that would arise from interpersonal growth patterns.  Additionally, the fact 
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that our study is prospective (versus retrospective) reduces potential selection bias, as the 
outcome variable is unknown at the time subjects are recruited. 
We recognize and have evaluated the limitations of our study.  The nature of the 
therapy we are studying does not allow for use of randomization or controlled assignment 
of study subjects to groups.  Patients are prescribed PD dialysis therapy, which includes 
glucose content, according to their specific and individual symptoms, volume status, and 
serum laboratory values.  Along these lines, use of a “placebo” PD group is unethical and 
potentially dangerous.  Manipulation of dialysis prescription, including dialysate glucose 
content, is also unethical and dangerous.  Placement of a PD catheter is a surgical 
procedure that is only indicated when a patient has an anticipated need for peritoneal 
dialysis therapy.  These factors prevent the use of an experimental study design (i.e. a 
randomized controlled trial) to investigate the relationship in question.  This said, the 
most accurate and ethical design is an observational, analytical prospective cohort study.  
The use of an observational study (versus an experimental study) introduces 
selection biases that would be avoided with random allocation of subjects to study arms.  
This also reduces the internal validity of our study.  However, for the above reasons, this 
bias was deemed unavoidable in light of the goals of our study. 
Recruiting from a consortium introduces potential response bias, in that this 
method of recruitment will limit to patients who have access to consortium/want to 
participate in research.  This may involve potential differences such as socioeconomic 
status or education level that would make our cohort different than the general population 
and therefore less generalizable to the population of pediatric ESRD patients as a whole.  
This could become relevant if our cohort had different eating/exercise habits than the 
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general population, confounding our potential association of weight change and treatment 
with PD.  However, in order for our study to remain feasible and able to be completed in 
a reasonable timeline, this method will be utilized. 
Lastly, our exclusion criteria limit our study population to pediatric patients who 
have not been on a method of dialysis in the past.  This reduces the external validity of 
our study, as some of the pediatric ESRD population initiating PD has been on a method 
of dialysis in the past.  According to the most recent data from the United States Renal 
Data System, a total of 1277 children were listed for renal transplant in the year 2013, 
447 of which had already been transplanted in the past and were being listed for a repeat 
transplant.1 This data report also states that pediatric repeat transplants range from 9-13% 
of total renal transplants over the years 2000-20131.  This said, a portion of children on 
RRT is waiting for a repeat transplant, and have likely been on a method of dialysis in the 
past.  ESRD is a disease that must be treated with RRT for the remainder of a patient’s 
life, often resulting in the use of different RRT methods as well as switching between 
methods based on the patient’s medical status. 
Clinical and Public Health Significance 
 
 Further understanding of the relationship between PD and weight change in the 
pediatric ESRD patient can contribute to improved clinical outcomes in these patients.  If 
PD’s effect on patient weight is better understood, dialysis prescription can be altered to 
improve outcomes in pediatric ESRD patients.  Additionally, improved understanding of 
the effects of peritoneal glucose load on weight change could stimulate further research 
into interventions or alternatives for use in dialyzed children, to avoid weight gain that is 
not explained by normal growth.  
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 Alternatives to dextrose-based solutions are currently being investigated for use in 
PD therapy.  Current research focuses on icodextrin solution use (a glucose polymer), and 
amino-acid solution use in peritoneal dialysis.2 Although at this time, icodextrin is only 
used for long-dwell peritoneal dialysis, and amino acid dialysate is not yet approved in 
this country, these options could change in availability and usage in the future.  Further 
understanding of the relationship of peritoneal glucose load and weight change in 
pediatric patients could significantly contribute to decisions regarding possible glucose 
alternative use in the pediatric population. 
Alternative biochemical PD solutions are currently being studied, including use of 
icodextrin, a glucose polymer, and use of amino acids as osmotic agents in the dialysate.  
Pharmacologically active agents, and bimodal long-dwell solutions are other alternatives 
currently being investigated in the field.2 
A 2010 study by Cho et al. comparing use of glucose based PD versus icodextrin 
based PD showed that the use of icodextrin resulted in less body weight and fat mass 
changes.3 This said, possibilities exist to improve dialysis prescription in pediatric 
patients by using alternative osmotic agents, but a better understanding of the effects of 
glucose as the osmotic agent is necessary to allow for improvements in dialysis 
prescription contents that are more biocompatible with pediatric patients and allow for 
better outcomes when treating these patients’ ESRD. 
Amino acid dialysate is an alternative to dextrose that is being investigated.  
Research shows that the use of amino acid based dialysate has resulted in lower serum 
glucose levels compared to glucose based dialysate solutions.4 It has not yet been 
approved for use in the U.S., but it could be available as an alternative to glucose use as 
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the osmotic agent in the future.  A study performed in Toronto found that in pediatric PD 
patients, amino acid usage as the dialysate osmotic agent was similar in effectiveness to 
glucose based dialysate usage.5 Measures of effectiveness included creatinine clearance, 
ultrafiltration, and absence of adverse effects.5 
Other things that can be done to reduce glucose exposure in PD patients involve 
improving ultrafiltration (removal of excess fluid across the peritoneal membrane during 
dialysis) efficiency and lessening the amount of glucose used to achieve peritoneal UF.6 
This can be done with fluid intake restriction and/or dietary sodium restriction.  
Hemodialysis is another option of RRT that can be used in the pediatric population.  
Alternatives to glucose based PD do exist in the pediatric population.  This said, 
understanding the relationship of glucose based PD to weight change and obesity in 
pediatric ESRD patients, which will arm providers with better abilities to prescribe RRT, 
is vital to optimal outcome.  
 The results of our study also have the potential for public health benefits, some of 
which pertain to a possible decreased time to renal transplantation.  As explained in 
Chapter 1, obesity can act as a barrier to renal transplantation or delay renal 
transplantation.  Expanding the knowledge base and tools available to prevent weight 
gain and obesity in dialyzed children could potentially lead to sooner renal 
transplantation in these children.  Not only could this improve the quality of life and 
clinical outcome of the child, but it could reduce the cost of treating the patient’s ESRD.  
Research shows that renal transplantation is more cost-effective than dialysis therapy.7 
The most recent data from the United States Renal Data System indicate that the per 
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patient per year cost of PD therapy is $69,919, while the per patient per year cost of renal 
transplantation ins 29,920.8 
Other potential public health benefits involve the cost and other consequences of 
obesity in the United States.  Although data gained from this study pertain to the pediatric 
ESRD population, pediatric obesity has long term effects, including future blood pressure 
and cardiovascular disease outcomes.9 The American Medical Association estimates 
obesity contributing to United States mortality rate with 112,000 deaths per year.9 The 
AMA characterizes these deaths as preventable.9 Additionally, obesity has a large 
economic burden, with the most recent data from the American Medical Association 
equating the cost of obesity (in 2008) over the duration of one year’s time to 147 billion 
dollars.9 This said, information that could potentially alleviate the burden of obesity in 
the pediatric population may, in turn, improve the country’s public health outcomes.  This 
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Appendix C: Parental Compound Authorization Form 
 
COMPOUND AUTHORIZATION AND PARENTAL PERMISSION FOR PARTICIPATION 
IN A RESEARCH PROJECT 
310 FR. 3a (2016-1)  
  
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Effect of Peritoneal Dialysis on Weight Change in Pediatric Patients 
Principal Investigator: Lindsey Belliveau, PA-SII 
 
Invitation to Participate and Description of Project 
 
We are inviting your child to participate in a research study designed to look 
at weight change in pediatric patients in their first year of PD therapy.  Your child has 
been asked to participate because he/she has been prescribed peritoneal dialysis to 
treat his/her renal disease.   
 
In order to decide whether or not you wish your child to be a part of this 
research study you should know enough about its risks and benefits to make an 
informed decision.  This permission form gives you detailed information about the 
research study, which a member of the research team will discuss with you.  This 
discussion should go over all aspects of this research: its purpose, the procedures that 
will be performed, and any risks of the procedures.  Once you understand the study, 
you will be asked if you wish your child to participate; if so, you will be asked to sign 
this form. 
 
Description of Procedures 
 
If you agree to your child participating in this study, we will record your child’s 
weight at the start of peritoneal dialysis therapy, and every six months thereafter for 
a total of 12 months.  At the start of the study, we will also record laboratory testing 
results and characteristics of your child like appetite and exercise level.   
 
➢ We will utilize your child’s past medical record to obtain past measurements of 
growth (height and weight) to predict how much their weight will change with 
normal growth during the 12 months of the study, which we will compare with 
their actual weight change during the study. 
➢ Under HIPAA the consent form and HIPAA Research Authorization form (RAF) 
can be combined for the same study, e.g., a single research purpose.  
 
Risks and Inconveniences 
 
➢ The measurements we will use in this study are things that are routinely done at 
dialysis checkups, regardless of study participation.  The only difference is that 
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we would be recording these measurements and using them for an additional 
purpose, to investigate the relationship of peritoneal dialysis use and weight 
change. 
➢ There are no physical risks associated with this study.  However there is the 
possible risk of loss of confidentiality.  Every effort will be made to keep your 




➢ There is no likelihood that your child will benefit directly from participation in 
this study, but the knowledge gained from using your child’s weight change and 
other measurements will add to the general scientific body of knowledge 
pertaining to peritoneal dialysis use in children.  Future endeavors based upon 
this study may improve the use of peritoneal dialysis therapy in children. 
 
Confidentiality and Privacy 
 
Any identifiable information that is obtained in connection with this study will 
remain confidential and will be disclosed only with your permission or as required 
by U.S. or State law.  Examples of information that we are legally required to disclose 
include abuse of a child or elderly person, or certain reportable diseases.  We will use 
a locked cabinet to store any written data obtained from this study, and only 
researchers directly employed by the study will have access to these data.  
Additionally, any electronic access of data will be done on encrypted devices by 
individuals employed by the study.   When the results of the research are published 
or discussed in conferences, no information will be included that would reveal your 
child’s identity unless your specific permission for this activity is obtained.   
 
We understand that information about your child obtained in connection with 
their health is personal, and we are committed to protecting the privacy of that 
information.  If you decide to allow your child to be in this study, the researcher will 
get information that identifies your child and his or her personal health information.  
This may include information that might directly identify your child, such as his or 
her name and age.  This information will be de-identified at the earliest reasonable 
time after we receive it, meaning we will replace your child’s identifying information 
with a code that does not directly identify him or her. The principal investigator will 
keep a link that identifies your child to his or her coded information, and this link will 
be kept secure and available only to the PI or selected members of the research team. 
Any information that can identify your child will remain confidential. The research 
team will only give this coded information to others to carry out this research study. 
The link to your child’s personal information will be kept for five years, after which 
time the link will be destroyed and the data will become anonymous. The data will be 
kept in this anonymous form indefinitely. 
   




Research study records 
• Medical and laboratory records of only those services provided in connection with 
this Study.   
• The entire research record and any medical records held by the child’s nephrologist 
or primary care provider used in the study 
• The following information:  
• Records about phone calls made as part of this research 
• Records about your child’s study visits 
Information obtained during this research regarding: 
Physical exams 
Laboratory, x-ray, and other test results 
 
Information about your child and your child’s health which might identify your child 
may be used by or given to:  
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Yale Human Investigation Committee (the committee that 
reviews, approves, and monitors research on human subjects), who are 
responsible for ensuring research compliance.  These individuals are 
required to keep all information confidential. 
• Those providers who are participants in the Electronic Medical Record 
(EMR) system. 
• Those individuals at Yale who are responsible for the financial oversight of 
research including billings and payments 
• The Principal Investigator Lindsey Belliveau 
• Governmental agencies to whom certain diseases (reportable diseases) must be 
reported 
• Health care providers who provide services to your child in connection with this 
study 
• Laboratories and other individuals and organizations that analyze your child’s 
health information in connection with this study, according to the study plan 
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the 
conduct of the Study 
•  
By signing this form, you authorize the use and/or disclosure of the information 
described above for this research study.  The purpose for the uses and disclosures you 
are authorizing is to ensure that the information relating to this research is available to 
all parties who may need it for research purposes. 
 
All health care providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your information.  The 
research staff at the Yale School of Medicine and Yale-New Haven Hospital are 
required to comply with HIPAA and to ensure the confidentiality of your child’s 
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information.  Some of the individuals or agencies listed above may not be subject to 
HIPAA and therefore may not be required to provide the same type of confidentiality 
protection. They could use or disclose your information in ways not mentioned in this 
form.  However to better protect your child’s health information, agreements are in 
place with these individuals and/or companies that require that they keep your 
information confidential.  
 
You have the right to review and copy your child’s health information in your child’s 
medical record in accordance with institutional medical records policies.  
 
This authorization to use and disclose your child’s health information collected 





➢ Your child’s name will be replaced with a numerical code when their data is 
stored for purposes of the study.  However, we will not be able to code other 
personal information, like age and sex, because this information will be used 
as a part of the data of our study.  However, all information recorded in this 
study will be stored in a locked cabinet, or on an encrypted computer/device. 
 
➢ Information about your child’s study participation will be entered into your 
child’s Electronic Medical Record (EMR). Once placed in your EMR, these 
results are accessible to all providers who participate in the EMR system. 
Information within your child’s EMR may also be shared with others who are 
appropriate to have access to your EMR (e.g. health insurance company, 
disability provider.) 
➢ Authorized representatives of the Food and Drug Administration (FDA) may 
need to review records of individual subjects.  As a result, they may see your 
name; but they are bound by rules of confidentiality not to reveal your identity 
to others. 
 
In Case of Injury 
 
If your child is injured while on study, seek treatment and contact the study 
doctor as soon as you are able.   
 
Yale School of Medicine and Yale-New Haven Hospital do not provide funds for 
the treatment of research-related injury.  If your child is injured as a result of 
his or her participation in this study, treatment will be provided.  You or your 
insurance carrier will be expected to pay the costs of this treatment.  No 
additional financial compensation for injury or lost wages is available. 
 




Voluntary Participation and Withdrawal 
 
You are free to choose not to have your child participate in this study. Refusing to 
participate will involve no penalty or loss of benefits to which your child is 
otherwise entitled (such as your child’s health care outside the study, the payment 
for your child’s health care, and your child’s health care benefits).   However, your 
child will not be able to enroll in this research study and will not receive study 
procedures as a study participant if you do not allow use of your child’s information 
as part of this study. 
  
Withdrawing From the Study 
 
If your child does become a subject, he or she is free to stop and withdraw from this 
study at any time during its course.  
 
To withdraw from the study, you can call a member of the research team at any time 
and tell them that your child no longer wants to take part.  This will cancel any 
future use of your child’s weight measurements and other data for the study. 
 
The researchers may withdraw your child from participating in the research if 
necessary.   
 
Withdrawing from the study will involve no penalty or loss of benefits to which your 
child is otherwise entitled. If your child chooses not to participate or if your child 
withdraws it will not harm your child’s relationship with your own doctors or with 
Yale-New Haven Hospital. 
 
Withdrawing Your Authorization to Use and Disclose Your Child’s Health Information 
 
You or your child may withdraw or take away his or her permission to use and 
disclose his or her health information at any time.  You do this by telling the study 
staff or by writing to the study doctor.  If you withdraw your permission, your child 
will not be able to stay in this study. 
 
When you withdraw your child’s permission, no new health information identifying 
your child will be gathered after that date.  Information that has already been 
gathered may still be used and given to others until the end of the research study, as 




➢  Data will have been anynomized, and your child’s name will be replaced by a 
numerical code.  Therefore, we will not be able to delete data that has already 
been obtained if your child withdraws from the study before the end of the study.  
However, if you child withdraws, we will not use their data in our analysis or any 
publication of the study. 
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➢ If there are medical needs required by the subject upon withdrawal, these should 
be stated.  Any follow-up procedures or assessments accompanying the 




We have used some technical terms in this form.  Please feel free to ask about 
anything you don't understand and to consider this research and the permission form 
carefully – as long as you feel is necessary – before you make a decision. 
 
Authorization and Permission 
 
I have read (or someone has read to me) this form and have decided to allow my child to 
participate in the project described above.  Its general purposes, the particulars of my 
child’s involvement and possible hazards and inconveniences have been explained to my 
satisfaction.  My signature also indicates that I have received a copy of this permission 
form. 
 
By signing this form, I give permission to the researchers to use [and give out] 
information about my child for the purposes described in this form.  By refusing to 
give permission, I understand that my child will not be able to be in this research.  
 
Name of Child: _____________________________
 
      
                                                       
 
Parent 1 Signature: ____________________         
Parent 2 Signature (if applicable):____________________          
 
Date: ________________________                       Date: ________________________ 
 
   
___________________________________________ ___________________ 
Signature of Person Obtaining Permission  Date 
 
If you have further questions about this project or if you have a research-related 
problem, you may contact the Principal Investigator: Lindsey Belliveau, 603-391-2743. 
 
If after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at (203) 432-5919  
 
If you would like to talk with someone other than the researchers to discuss problems, 
concerns, and questions you may have concerning this research, or to discuss your rights 














Child’s Assent for Being in a Research Study 
Yale-New Haven Hospital/Yale University School of Medicine 
 
Title: Effect of Dialysis on Weight Change 
 
Why am I here? 
 We are asking you to take part in a research study because we are trying to learn 
more about dialysis therapy and weight change. We are inviting you to be in the study 
because you have been prescribed peritoneal dialysis (PD) treatment by your nephrologist 
(kidney doctor). 
 
Why are they doing this study? 
 They are doing this study to see if children on PD have weight change, in addition 
to the normal weight you gain as you grow.  If PD causes this weight change, doctors may 
be able to help people on PD to prevent this from happening in the future. 
 
What will happen to me? 
You will be weighed on a scale each time you have a dialysis checkup.  You will 
also be asked about your appetite, daily activities during the study.  We will also 
get some tests done to your blood, that are regularly done at dialysis checkups.  
Some of these measurements will be used in the study. 
 
Will the study hurt? 
 The study will not hurt, and there will be no risks to being in the study.  The study 
uses measurements that are regularly done at dialysis checkups. 
 
What if I have any questions? 
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 You can ask any questions that you have about the study. If you have a question 
later that you didn’t think of now, you can call me or ask me next time.  
 
Do my parents know about this? 
This study was explained to your parents and they said that you could be in it.  
You can talk this over with them before you decide. 
 
Do I have to be in the study? 
 You do not have to be in the study.  No one will be upset if you don’t want to do 
this.  If you don’t want to be in this study, you just have to tell them.  You can say yes now 
and change your mind later.  It's up to you. 
 
Writing your name on this page means that that you agree to be in the study, and know 





_________________________________________                  ___________________ 
Signature of Child       Date 
 
_________________________________________                  ___________________ 







Appendix E: Adolescent (age 13-17) Assent Form 
 
ADOLESCENT ASSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
310 FR 3 (2016-1) 
 
Study Title: Effect of Peritoneal Dialysis on Weight Change in Pediatric Patients 
Principal Investigator: Lindsey Belliveau, PA-SII 
 
Invitation to Participate and Description of Project 
 
You are invited to take part in a research study that will look at weight change 
in children on peritoneal dialysis therapy.  You have been asked to take part because 
your doctor has prescribed peritoneal dialysis to treat your kidney disease.  Between 
50-100 patients will take part in this study, in hospitals and dialysis centers across 
the United States. 
 
In order to decide whether or not you wish to be a part of this research study, 
you should know enough about its risks and benefits to make an informed decision.  
This assent form gives you detailed information about the study, which a member of 
the research team will discuss with you and your parents.  This discussion should go 
over all aspects of this research: its purpose, the procedures that will be performed, 
and any risks of the procedures.  
 
If you agree to be in this study, we will record your weight at the start of 
peritoneal dialysis therapy, and every six months thereafter for a total of 12 months.  
At the start of the study, we will also record some of your laboratory testing results 




➢ We will utilize your past medical record to obtain past measurements of growth 
(height and weight) to predict how much your weight will change with normal 
growth during the 12 months of the study, which we will compare with your 
actual weight change during the study. 
 
➢ Under HIPAA the consent form and HIPAA Research Authorization form (RAF) 
can be combined for the same study, e.g., a single research purpose.  
 
Risks and Inconveniences 
 
➢ The measurements we will use in this study are things that are routinely done at 
dialysis checkups, regardless of study participation.  The only difference is that 
we would be recording these measurements and using them for an additional 
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purpose, to investigate the relationship of peritoneal dialysis use and weight 
change. 
 
➢ There are no physical risks associated with this study.  However there is the 
possible risk of loss of confidentiality.  Every effort will be made to keep your 






➢ There is no likelihood that you will benefit directly from participation in this 
study, but the knowledge gained from using your weight change and other 
measurements will add to the general scientific body of knowledge pertaining to 
peritoneal dialysis use in children.  Future endeavors based upon this study may 
improve the use of peritoneal dialysis therapy in children. 
 




➢ We will use a numerical code to replace your name when recording data for 
our study.  However, we will not be able to code other personal information, 
like age and sex, because this information will be used as a part of the data of 
our study.  However, all information recorded in this study will be stored in a 
locked cabinet, or on an encrypted computer/device. 
➢ Information about your study participation will be entered into your 
Electronic Medical Record (EMR). Once placed in your EMR, these results are 
accessible to all providers who participate in the EMR system. Information 
within your EMR may also be shared with others who are appropriate to 
have access to your EMR (e.g. health insurance company, disability provider.) 
➢ Authorized representatives of the Food and Drug Administration (FDA) may 
need to review records of individual subjects.  As a result, they may see your 
name; but they are bound by rules of confidentiality not to reveal your identity 
to others. 
 
Any identifiable information that we obtain about you during this study will stay 
confidential and will be shared only if you agree to it.  There are also situations where 
we would have to release your identifiable information (your name for example) 
according to the U.S. or State law.  Examples of information that we have to report to 
authorities include abuse of a child, certain reportable diseases (such as being HIV 
positive or having Hepatitis B), or when we believe you may harm yourself or 
someone else. When the results of the research are published or discussed in 
conferences, no information will be included that would reveal your identity unless 




We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information.  If you decide to be in this study, the researchers 
will get information that identifies you and your personal health information.  For example, 
we will collect age and sex.  This information will be de-identified as soon as possible, 
which means that we will replace your identifying information with a code. The principal 
investigator (the person who is responsible for this research) will keep a link that matches 
you to your coded information, and this link will be kept safe and available only to a few 
people on this research team. The link to your personal information will be kept for five 
years, and then it will be destroyed and the data will become anonymous. The data will be 
kept in this anonymous form indefinitely. We will use a locked cabinet to store any written 
data obtained from this study, and only researchers directly employed by the study will 
have access to these data.  Additionally, any electronic access of data will be done on 
encrypted devices by individuals employed by the study. The research team will only give 
coded information to others to carry out this research study.  
 
The information about your health that will be collected in this study includes:  
 
• Research study records 
• Medical and laboratory records of only those services provided in connection with 
this Study.   
• The entire research record and any medical records obtained during the study 
• The following information: 
•    Records about phone calls made as part of this research 
•  Records about your study visits 
 
Information about you and your health may be used by or given to:  
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale Human Research Protection Program and the Yale 
Human Investigation Committee (the committee that reviews, approves, and 
monitors research on human subjects), who are responsible for ensuring 
research compliance.  These individuals are required to keep all information 
confidential.  
• Those providers who are participants in the Electronic Medical Record 
(EMR) system. 
• Those individuals at Yale who are responsible for the financial oversight of 
research including billings and payments 
• The Principal Investigator Lindsey Belliveau 
 
 
Select as appropriate the following additional groups with whom the data may be 
shared and delete those that do not apply. 
 
• The U.S. Food and Drug Administration (FDA)  




• Health care providers who provide services to you in connection with this study. 
• Laboratories and other individuals and organizations that analyze your health 
information in connection with this study, according to the study plan. 
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the 
conduct of the Study: List any separate or local committees not in the protocol, 
if applicable 
 
By signing this form, you let us use the information in the way we described above for 
this research study.  This authorization to use and disclose your health information 
collected during your participation in this study will never expire. 
 
The research staff at the Yale School of Medicine and Yale New Haven Hospital have to 
obey the privacy laws and make sure that your information stays confidential.  Some of 
the people or agencies listed above may not have to obey those laws, which means that 
they do not have to protect the data in the same way we do. They could use or share your 
information in ways not mentioned in this form.  However, to better protect your health 
information, agreements are in place with these individuals and/or companies that 
require that they keep your information confidential.  
 
In Case of Injury 
 
If you are injured while on study, seek treatment and contact the study 
doctor as soon as you are able.   
 
Yale School of Medicine and Yale New Haven Hospital do not provide funds for 
the treatment of research-related injury.  If you are injured as a result of your 
participation in this study, treatment will be provided.  Your parents or your 
insurance carrier will be expected to pay the costs of this treatment.  No 
additional financial compensation for injury or lost wages is available. 
 
You do not give up any of your legal rights by signing this form. 
 
Voluntary Participation and Withdrawal 
 
You do not have to take part in this study.  Refusing to participate will involve no 
penalty or loss of benefits to which you are otherwise entitled (such as your health 
care outside the study, the payment for your health care, and your health care 
benefits). Your health care outside the study will not change if you do not agree to 
participate.  However, you will not be able to enroll in this research study and will 
not receive study procedures as a study participant if you do not allow use of your 
information as part of this study. 
 




If you decide to take part in this study, and then change your mind, you can always 
stop and withdraw from this study at any time during its course.  Withdrawing from 
the study will involve no penalty or loss of benefits to which you are otherwise 
entitled.  It will not harm your relationship with your own doctors or with Yale New 
Haven Hospital. 
 
To stop your participation in the study, you can call a member of the research team 
at any time and tell them that you no longer want to take part.  This will cancel any 
future appointments. 
 
The researchers may withdraw you from participating in the research if necessary.  
 
Withdrawing your Authorization to Use and Share Your Health Information 
 
If you do not want researchers to use and disclose your health information as 
described in the Confidentiality section, you and your parent(s) may withdraw your 
permission by telling the study staff or by writing to Lindsey Belliveau at the Yale 
University Physician Associate Program, New Haven, CT 06520. 
When you do that, no new health information identifying you will be collected after 
that date. Again, the investigators will be able to use the information that they already 
collected about you to finish the study.  
 




We have used some complicated terms in this form.  Please feel free to ask 
about anything you don't understand and to think about this research and the assent 
form carefully – as long as you need to – before you make a decision. We encourage 
that you talk to your family about your decision as well. If you come up with questions 
after reading this form, you can call me at 603-391-2743. 
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Authorization and Permission 
 
I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the things I will do in the study and possible 
risks and inconveniences have been explained to my satisfaction.  My signature also shows 
that I have been given a copy of this assent form. 
 
By signing this form, I give permission to the researchers to use [and give out] 
information about me for the reasons described in this form.  If I decide not to give 
permission, I understand that I will not be able to be in this research.  
 
Name of Subject: _____________________________
 
      






   
___________________________________________ ___________________ 
Signature of Person Obtaining Assent  Date 
 
If you have further questions about this project or if you have a research-related 
problem, you may contact the Principal Investigator Lindsey Belliveau, 603-391-
2743.  If you would like to talk with someone other than the researchers to discuss 
problems, concerns, and questions you may have concerning this research, or to discuss 
your rights as a research subject, you may contact the Yale Human Investigation 
Committee at (203) 785-4688. If after you have signed this form you have any questions 





Appendix F: Data Collection Form 
 
 
Patient Identification Number: _______________________________ 
 
 





Primary diagnosis leading to ESRD  
Peritoneal Equilibration Test results  
Laboratory values  
Socioeconomic Status  
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Daily dialysate 
volume  
             
Appetite              
Physical 
Activity Level 
             
 
Weight from prior health records 
 
















Expected weight change (from CDC growth 




Secondary Outcome (Weight change) Calculation 
 
Weight Change= (Actual weight change) – (Expected Weight Change) 
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CDC growth charts (kg) 















Months of PD Use Actual weight (kg) 
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